Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001493152-22-035273
Filing Date
2022-12-13
Accepted
2022-12-13 10:43:58
Documents
2
Period of Report
2022-12-12

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 1604
2 ex-24.htm EX-24 8663
  Complete submission text file 0001493152-22-035273.txt   11700
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Issuer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ZYVERSA THERAPEUTICS, INC. 2200 N. COMMERCE PARKWAY WESTON FL 33326
Business Address
Wolfe Peter (Reporting) CIK: 0001954398 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41184 | Film No.: 221458820